Molecular Infectious Disease Testing Market to Hit USD 34.73 Billion by 2034, Exhibiting a CAGR of 13.5%

Global Molecular Infectious Disease Testing Market size and share is currently valued at USD 9.78 billion in 2024 and is anticipated to generate an estimated revenue of USD 34.73 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 13.5% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

Market Definition

The Molecular Infectious Disease Testing Market plays a crucial role in rapidly diagnosing infections using nucleic acid-based technologies such as PCR (Polymerase Chain Reaction) and isothermal amplification. These tests detect pathogens with high specificity and sensitivity, aiding in timely and accurate treatment decisions. The COVID-19 pandemic significantly accelerated the development and adoption of molecular diagnostics, establishing them as a cornerstone in global health management. Market growth is driven by increasing incidences of infectious diseases, technological advancements in multiplex testing, and demand for point-of-care diagnostics. Innovations like CRISPR-based detection and portable testing kits are expanding diagnostic capabilities even in low-resource settings. Furthermore, growing awareness about antimicrobial resistance and the importance of early detection is boosting demand. However, high costs and complex regulatory requirements remain challenges. With continuous R&D and the integration of AI in data interpretation, the market is expected to evolve, playing an even more vital role in public health and epidemic preparedness.

Key Report Highlights

The report highlights the key region that accounts for the highest revenue share in the global Molecular Infectious Disease Testing market.
It identifies the leading country within this region that makes a significant contribution to the market’s overall performance.
The report outlines the dominant segment that holds a major share of the market.
It also emphasizes the fastest-growing segment projected to gain strong traction during the forecast period.
Qualitative and quantitative market analysis have been used to provide an in-depth understanding of the market.

Market Overview: Key Figures at a Glance

Market Value in 2024: USD 9.78 billion
Projected Market Size in 2034: USD 34.73 billion
Anticipated CAGR (2025-2034): 13.5%

Get access to the full report or request a complimentary sample for in-depth analysis:

https://www.polarismarketresearch.com/industry-analysis/molecular-infectious-disease-testing-market/request-for-sample

Market Growth Drivers

The surge in infectious disease outbreaks—like COVID-19, monkeypox, and various antibiotic-resistant bacteria—has intensified the need for rapid, accurate, and sensitive diagnostic methods. Molecular testing, including PCR and isothermal nucleic acid amplification, has emerged as a gold standard due to its ability to detect pathogens at extremely low concentrations. Governments and healthcare institutions are heavily investing in molecular diagnostics infrastructure to enable early detection and containment of infectious diseases. The trend toward personalized medicine and point-of-care diagnostics is further pushing demand. Moreover, increased awareness among the public and clinicians about the importance of early diagnosis is boosting testing rates. Technological advancements such as multiplex assays, automated platforms, and miniaturized portable devices are also expanding the reach and convenience of molecular testing. These developments are collectively propelling the molecular infectious disease testing market toward consistent growth.

Market Key Players

The competitive landscape features a mix of long-standing companies and emerging contenders. Leading players are actively pursuing R&D initiatives and strategic moves to strengthen their market position. Notable participants include